Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Current Investments (2018 - 2025)

Addex Therapeutics' Cash & Current Investments history spans 8 years, with the latest figure at $2.1 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 46.19% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 46.19% decrease, with the full-year FY2025 number at $2.0 million, down 48.13% from a year prior.
  • Cash & Current Investments came in at $2.1 million for Q4 2025, down from $2.7 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $22.2 million in Q4 2021, with the low at $490.17 in Q3 2023.
  • Historically, Cash & Current Investments has averaged $9.2 million across 5 years, with a median of $4.3 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: tumbled 100.0% in 2023 and later skyrocketed 47908.68% in 2025.
  • Year by year, Cash & Current Investments stood at $22.2 million in 2021, then plummeted by 67.51% to $7.2 million in 2022, then crashed by 39.67% to $4.4 million in 2023, then decreased by 12.31% to $3.8 million in 2024, then crashed by 46.19% to $2.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for ADXN at $2.1 million in Q4 2025, $2.7 million in Q3 2025, and $2.8 million in Q2 2025.